Search by Drug Name or NDC

    NDC 00006-5368-07 STEGLUJAN 15; 100 mg/1; mg/1 Details

    STEGLUJAN 15; 100 mg/1; mg/1

    STEGLUJAN is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is ERTUGLIFLOZIN PIDOLATE; SITAGLIPTIN PHOSPHATE.

    Product Information

    NDC 00006-5368
    Product ID 0006-5368_21cf231e-a04e-4f5b-82ab-b872482550f9
    Associated GPIs 27996502350330
    GCN Sequence Number 078037
    GCN Sequence Number Description ertugliflozin/sitagliptin phos TABLET 15MG-100MG ORAL
    HIC3 C4W
    HIC3 Description ANTIHYPERGLYCEMIC, SGLT-2 AND DPP-4 INHIBITOR COMB
    GCN 44238
    HICL Sequence Number 044706
    HICL Sequence Number Description ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
    Brand/Generic Brand
    Proprietary Name STEGLUJAN
    Proprietary Name Suffix n/a
    Non-Proprietary Name ertugliflozin and sitagliptin
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED
    Route ORAL
    Active Ingredient Strength 15; 100
    Active Ingredient Units mg/1; mg/1
    Substance Name ERTUGLIFLOZIN PIDOLATE; SITAGLIPTIN PHOSPHATE
    Labeler Name Merck Sharp & Dohme LLC
    Pharmaceutical Class Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA209805
    Listing Certified Through 2024-12-31

    Package

    NDC 00006-5368-07 (00006536807)

    NDC Package Code 0006-5368-07
    Billing NDC 00006536807
    Package 500 TABLET, FILM COATED in 1 BOTTLE (0006-5368-07)
    Marketing Start Date 2017-12-19
    NDC Exclude Flag N
    Pricing Information N/A